Shionogi’s Fetroja Contract And Data Shift U.S. Growth And Valuation Outlook

Shionogi has received a major U.S. government contract to manufacture its antibiotic Fetroja domestically. New real world ...

Shionogi secures $482m BARDA contract to tackle AMR crisis

This funding will boost the US’s antibiotic manufacturing capacity, while helping to curb the threat of antimicrobial ...

Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats

Program Includes Establishing Pharmaceutical Manufacturing in the U.S., Procurement and Development of Treatment for Infections Caused by Biothreat Pathogens OSAKA, Japan--(BUSINESS WIRE)--April 08, ...
Fierce Pharma

Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant

Japan’s Shionogi is joining the spate of drugmakers to announce manufacturing commitments in the U.S. since last year, albeit ...
PharmExec

Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats

The U.S. government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja ...
CIDRAP

Shionogi secures BARDA contract for cefiderocol for resistant infections, bioterror threats

Japanese drugmaker Shionogi announced yesterday that its US subsidiary has received a $119 million contract from the US ...
PharmExec

Pharmaceutical Executive Daily: Shionogi Receives Contract Through BARDA's Project BioShield

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
PharmiWeb

ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterale…

Real-world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day ...
Business Wire

IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously Ill Patients

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces new data at IDWeek 2024 from PROVE ...